Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VH4011499 Phase 1 in healthy volunteers
NCT06724640Phase 1Recruiting
- Sponsor
- ViiV Healthcare
- Start
- Dec 2024
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VH4011499 in human immunodeficiency virus infection (HIV) (6 arms), sponsored by ViiV Healthcare. Primary endpoints: Adverse Events at 78 weeks, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity at 78 weeks and 4 more. Started Dec 2024; status: recruiting.
02
Drugs
VH4011499
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06724640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06724640.